Real-world test of promising breast cancer drug begins
NCT ID NCT07358182
First seen Jan 23, 2026 · Last updated May 05, 2026 · Updated 15 times
Summary
This study looks at how well a drug called trastuzumab-rezetecan works and how safe it is for people with HER2-positive or HER2-low breast cancer. Researchers will follow 300 patients who are already getting or will get this drug as part of their normal care. The goal is to see real-world results, including side effects and how the cancer responds, without changing the treatment plan chosen by their doctor.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2-POSITIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Breast Tumor Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University
RECRUITINGGuangzhou, Guangdong, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.